scholarly article | Q13442814 |
P50 | author | Marc N. Potenza | Q25336883 |
P2093 | author name string | Scott A Bullock | |
P2860 | cites work | Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review | Q24602117 |
Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability | Q24633664 | ||
The neurobiology and genetics of impulse control disorders: relationships to drug addictions | Q24642641 | ||
The Iowa Gambling Task in fMRI images | Q24644313 | ||
How stress influences the immune response | Q28156366 | ||
Patterns and correlates of Gamblers Anonymous attendance in pathological gamblers seeking professional treatment | Q28183554 | ||
Gamblers anonymous and cognitive-behavioral therapies for pathological gamblers | Q28241596 | ||
Cue-induced brain activity in pathological gamblers | Q28259573 | ||
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion | Q29547251 | ||
The neural basis of addiction: a pathology of motivation and choice | Q29615901 | ||
Dopamine modulates reward expectancy during performance of a slot machine task in rats: evidence for a 'near-miss' effect | Q30499625 | ||
Knowing when to stop: the brain mechanisms of chasing losses | Q48091629 | ||
An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers | Q48156393 | ||
N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study | Q48196146 | ||
Gambling urges in pathological gambling: a functional magnetic resonance imaging study | Q48229227 | ||
Exploring the neurological substrate of emotional and social intelligence | Q48282101 | ||
Adolescent risky decision-making: neurocognitive development of reward and control regions | Q48290725 | ||
Psychiatry. Behavioral addictions debut in proposed DSM-V. | Q48301277 | ||
Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo | Q48422105 | ||
Pathological gambling is linked to reduced activation of the mesolimbic reward system | Q49157389 | ||
Altered CSF 5-HIAA Disposition in Pathologic Male Gamblers. | Q51452792 | ||
Decision threshold modulation in the human brain. | Q51643403 | ||
A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. | Q51901560 | ||
Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. | Q52029001 | ||
Casino gambling increases heart rate and salivary cortisol in regular gamblers. | Q52279108 | ||
Molecular mechanisms of drug addiction | Q59410663 | ||
Pathological gambling in Parkinson disease is reduced by amantadine | Q62078600 | ||
Treatment of pathological gambling with clomipramine | Q68109459 | ||
Comparison of Imaginal Desensitisation with other Behavioural Treatments of Pathological Gambling a Two- to Nine-Year Follow-up | Q68325596 | ||
A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling | Q73794738 | ||
Short-term single-blind fluvoxamine treatment of pathological gambling | Q77646710 | ||
Cognitive-behavioral therapy for pathological gamblers | Q79843013 | ||
Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation | Q83317495 | ||
Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. | Q46487082 | ||
Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity | Q46516282 | ||
Cue-induced brain activity changes and relapse in cocaine-dependent patients | Q46670523 | ||
A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers | Q46763037 | ||
Cerebrospinal fluid amino acids in pathological gamblers and healthy controls | Q46765277 | ||
Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study | Q46800105 | ||
Gambling, health and age: data from the National Epidemiologic Survey on Alcohol and Related Conditions | Q31139593 | ||
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients | Q33574373 | ||
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study | Q33770775 | ||
Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling | Q33948583 | ||
Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. | Q34024174 | ||
A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling | Q34135868 | ||
Animal models of neuropsychiatric disorders. | Q34158236 | ||
Effort-based cost-benefit valuation and the human brain | Q34194322 | ||
Pathological Gamblers Respond Equally Well to Cognitive‐Behavioral Therapy Regardless of Other Mental Health Treatment Status | Q34222695 | ||
Separate neural systems value immediate and delayed monetary rewards | Q34359177 | ||
Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? | Q34380515 | ||
Pathological gambling. A psychobiological study | Q34403473 | ||
Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study | Q34457635 | ||
Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking | Q34480486 | ||
Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study | Q34616679 | ||
A pilot trial of topiramate for the treatment of cocaine dependence | Q34649737 | ||
Cognitive-behavioral treatment for impulse control disorders | Q34666303 | ||
Neuroscience of behavioral and pharmacological treatments for addictions | Q34714494 | ||
Are there cognitive and behavioural approaches specific to the treatment of pathological gambling? | Q35084959 | ||
Dopaminergic network differences in human impulsivity | Q35180321 | ||
Gambling and problem gambling across the lifespan | Q35247976 | ||
Biologic correlates of suicidal risk and aggressive behavioral traits | Q35316957 | ||
Separate neural mechanisms underlie choices and strategic preferences in risky decision making | Q35541448 | ||
Glutamate transmission in addiction | Q35759473 | ||
The neurobiology of pleasure, reward processes, addiction and their health implications | Q35884695 | ||
An fMRI study of risk-taking following wins and losses: implications for the gambler's fallacy. | Q36194373 | ||
Anticraving medications for relapse prevention: a possible new class of psychoactive medications | Q36213564 | ||
Outcome of psychological treatments of pathological gambling: a review and meta-analysis | Q36268436 | ||
A 6-month follow-up of imaginal desensitization plus motivational interviewing in the treatment of pathological gambling | Q36302186 | ||
Gambling and substance use disorders: current status and future directions | Q36761341 | ||
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway | Q36877274 | ||
Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis | Q36882312 | ||
Pathological gambling and substance use disorders | Q36898993 | ||
Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? | Q36900876 | ||
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling | Q36931279 | ||
Differential activation of the anterior cingulate cortex and caudate nucleus during a gambling simulation in persons with a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project | Q37087740 | ||
Gambling near-misses enhance motivation to gamble and recruit win-related brain circuitry | Q37135701 | ||
Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses | Q37235478 | ||
Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine | Q37245343 | ||
A randomized trial of brief interventions for problem and pathological gamblers | Q37335038 | ||
Genetics of dopamine receptors and drug addiction: a comprehensive review | Q37380521 | ||
Reconciling the role of serotonin in behavioral inhibition and aversion: acute tryptophan depletion abolishes punishment-induced inhibition in humans | Q37418144 | ||
A systematic review and meta-analysis of cognitive-behavioural interventions to reduce problem gambling: hedging our bets? | Q37484593 | ||
GABAB receptors in reward processes | Q37775215 | ||
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Norepinephrine and Epinephrine Systems | Q38063416 | ||
Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. | Q38392427 | ||
A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers | Q38400678 | ||
Controlled Comparison of Aversive Therapy and Imaginal Desensitization in Compulsive Gambling | Q39559941 | ||
Preference for immediate over delayed rewards is associated with magnitude of ventral striatal activity. | Q40258311 | ||
Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate | Q40636826 | ||
Motivational interviewing: research, practice, and puzzles | Q41199396 | ||
Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines | Q41222875 | ||
Endogenous opioid systems and alcohol addiction | Q41353548 | ||
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study | Q42637052 | ||
Sertraline treatment of pathological gambling: a pilot study | Q42646084 | ||
Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study | Q43001389 | ||
Predicting treatment response to naltrexone: the influence of craving and family history | Q43752726 | ||
Localization of GABA(B) receptors in midbrain monoamine containing neurons in the rat. | Q43768846 | ||
The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. | Q43770574 | ||
Divalproex loading in the treatment of cocaine dependence | Q43805757 | ||
A pilot placebo-controlled study of fluvoxamine for pathological gambling. | Q44015745 | ||
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study | Q44023429 | ||
Lithium and valproate treatment of pathological gambling: a randomized single-blind study. | Q44080281 | ||
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients | Q44341917 | ||
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling | Q44351769 | ||
A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. | Q44441093 | ||
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse | Q44460612 | ||
Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial | Q44484632 | ||
N-acetyl cysteine-induced blockade of cocaine-induced reinstatement | Q44698807 | ||
Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. | Q44731806 | ||
Central catecholamine neuron systems: anatomy and physiology of the dopamine systems | Q44795666 | ||
A double-blind, placebo-controlled trial of topiramate for pathological gambling | Q44835101 | ||
Neuroendocrine response to casino gambling in problem gamblers | Q45003458 | ||
Serotonergic modulation of prefrontal cortex during negative feedback in probabilistic reversal learning | Q45250168 | ||
Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study | Q45265367 | ||
Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics. | Q45950040 | ||
Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. | Q45964632 | ||
A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling | Q46064407 | ||
FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism | Q46379152 | ||
P433 | issue | 1 | |
P921 | main subject | problem gambling | Q748309 |
P577 | publication date | 2012-02-01 | |
P1433 | published in | Current psychopharmacology | Q27724959 |
P1476 | title | Pathological Gambling: Neuropsychopharmacology and Treatment | |
P478 | volume | 1 |
Q37146962 | A targeted review of the neurobiology and genetics of behavioural addictions: an emerging area of research |
Q37066444 | Commentary on Boileau et al. (2013): Distinguishing D2/D3 dopaminergic contributions to addictions |
Q64930735 | Diagnostic and Classification Considerations Regarding Gaming Disorder: Neurocognitive and Neurobiological Features. |
Q35690154 | Gambling disorder and other behavioral addictions: recognition and treatment |
Q37408538 | How central is dopamine to pathological gambling or gambling disorder? |
Q26781480 | Measuring anhedonia: impaired ability to pursue, experience, and learn about reward |
Q38835538 | Mirtazapine and ketanserin alter preference for gambling-like schedules of reinforcement in rats |
Q37243020 | Neurobiology of gambling behaviors |
Q64910100 | Pharmacological Treatments for Disordered Gambling: A Meta-analysis. |
Q38840362 | Telecommunications Network Measurements of Online Gambling Behavior in Switzerland: A Feasibility Study. |
Q33955187 | The neural bases of cognitive processes in gambling disorder |
Q33698391 | Treatment of Gambling Disorders |
Q34453625 | Update on the Pharmacological Treatment of Pathological Gambling |
Search more.